ArticleBrain sciences2026
Protective Effects of Gallic Acid on Oxidative and Inflammatory Markers in the Hippocampus and Prefrontal Cortex of a Ketamine-Induced Schizophrenia-like Model.
Article in Brain sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSchizophrenia is a chronic neuropsychiatric disorder characterized by cognitive impairment, behavioral abnormalities, neuroinflammation, and oxidative stress. Increasing evidence suggests that dysregulated inflammatory cytokines and impaired antioxidant defenses contribute to schizophrenia pathophysiology. This study investigated the neuroprotective and anti-inflammatory effects of Gallic Acid (GA) in a ketamine-induced experimental schizophrenia model.
methodsThirty male Balb/C mice were randomly divided into control, ketamine, and ketamine + GA groups. Schizophrenia was induced with ketamine (25 mg/kg/day) for 7 days, while the treatment group additionally received GA (60 mg/kg/day) for another 7 days. Behavioral tests, including open field, novel object recognition, and tail suspension tests, were performed to evaluate locomotor activity, cognition, and depressive-like behavior. Tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-18 (IL-18), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), total antioxidant status (TAS), and total oxidant status (TOS) levels were analyzed in hippocampal and prefrontal cortex tissues to assess inflammatory and oxidative stress-related alterations.
resultsKetamine induced schizophrenia-like behaviors, including hyperlocomotion, memory impairment, and increased immobility. These behavioral alterations were accompanied by significantly elevated TNF-α, IL-1β, IL-18, and TOS levels, alongside reduced SOD, CAT, GSH-Px, and TAS levels in the hippocampus and prefrontal cortex. GA treatment ameliorated behavioral impairments, restored antioxidant enzymes, increased TAS levels, and reduced pro-inflammatory cytokines and TOS in these brain regions.
conclusionsGA exerted neuroprotective effects in the ketamine-induced schizophrenia model by reducing oxidative stress, neuroinflammation, and behavioral deficits. These findings suggest that Gallic Acid may serve as a promising therapeutic candidate for schizophrenia through modulation of inflammatory and oxidative stress pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.